Literature DB >> 6043735

Experimental evaluation of potential anticancer agents. XXI. Scheduling of arabinosylcytosine to take advantage of its S-phase specificity against leukemia cells.

H E Skipper, F M Schabel, W S Wilcox.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1967        PMID： 6043735

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN： 0069-0112


× No keyword cloud information.
  39 in total

1.  Chronobiology.

Authors:  E R Burns
Journal:  Pavlov J Biol Sci       Date:  1975 Jul-Sep

2.  Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.

Authors:  Jeffrey E Lancet; Jorge E Cortes; Donna E Hogge; Martin S Tallman; Tibor J Kovacsovics; Lloyd E Damon; Rami Komrokji; Scott R Solomon; Jonathan E Kolitz; Maureen Cooper; Andrew M Yeager; Arthur C Louie; Eric J Feldman
Journal:  Blood       Date:  2014-03-31       Impact factor: 22.113

3.  In vivo antiviral properties of biologically active compounds. II. Studies with influenza and vaccinia viruses.

Authors:  R W Sidwell; G J Dixon; S M Sellers; F M Schabel
Journal:  Appl Microbiol       Date:  1968-02

4.  Enhanced retention of cytosine arabinoside and its metabolites and synergistic cytotoxicity by sequential treatment with dipyridamole in L5178Y leukemia.

Authors:  J L Yang; J C White; R L Capizzi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Timed sequential chemotherapy following ifosfamide-induced kinetic recruitment in refractory ovarian cancer.

Authors:  R Rosso; A Alama; L Repetto; P F Conte
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

6.  Preliminary results of chemo-radiotherapy followed or not by active immunotherapy of stage III and IV lymphosarcoma and reticulosarcoma. Correlation of the results with WHO categorisation.

Authors:  J L Misset; G Mathé; M Tubiana; B Caillou; F de Vassal; P Pouillart; M Gil; C Tentas; M Hayat; L Schwarzenberg; C Jasmin; M Delgado; D Machover; P Ribaud; M Musset
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

7.  Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions.

Authors:  S B Howell; B B Chu; W E Wung; B M Metha; J Mendelsohn
Journal:  J Clin Invest       Date:  1981-04       Impact factor: 14.808

8.  Cell proliferation in human melanoma.

Authors:  S Shirakawa; J K Luce; I Tannock; E Frei
Journal:  J Clin Invest       Date:  1970-06       Impact factor: 14.808

9.  Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo.

Authors:  D A Carson; D B Wasson; J Kaye; B Ullman; D W Martin; R K Robins; J A Montgomery
Journal:  Proc Natl Acad Sci U S A       Date:  1980-11       Impact factor: 11.205

10.  The 9L rat brain tumor: description and application of an animal model.

Authors:  M Weizsaecker; D F Deen; M L Rosenblum; T Hoshino; P H Gutin; M Barker
Journal:  J Neurol       Date:  1981       Impact factor: 4.849
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.